Literature DB >> 9459295

Isolation and characterization of the circulating form of human endostatin.

L Ständker1, M Schrader, S M Kanse, M Jürgens, W G Forssmann, K T Preissner.   

Abstract

Recently, fragments of extracellular proteins, including endostatin, were defined as a novel group of angiogenesis inhibitors. In this study, human plasma equivalent hemofiltrate was used as a source for the purification of high molecular weight peptides (10-20 kDa), and the isolation and identification of circulating human endostatin are described. The purification of this C-terminal fragment of collagen alpha1(XVIII) was guided by MALDI-MS and the exact molecular mass determined by ESI-MS was found to be 18 494 Da. N-terminal sequencing revealed the identity of this putative angiogenesis inhibitor and its close relation to mouse endostatin. The cysteine residues 1-3 and 2-4 in the molecule are linked by disulfide bridges. In vitro biological characterization of the native protein demonstrated no anti-proliferative activity on different endothelial cell types. These data indicate that human endostatin, which is a putative angiogenesis inhibitor, is present in the circulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9459295     DOI: 10.1016/s0014-5793(97)01503-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  23 in total

Review 1.  New functional roles for non-collagenous domains of basement membrane collagens.

Authors:  Nathalie Ortega; Zena Werb
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

2.  Lack of collagen XVIII/endostatin exacerbates immune-mediated glomerulonephritis.

Authors:  Yuki Hamano; Takashi Okude; Ryota Shirai; Ikumi Sato; Ryota Kimura; Makoto Ogawa; Yoshihiko Ueda; Osamu Yokosuka; Raghu Kalluri; Shiro Ueda
Journal:  J Am Soc Nephrol       Date:  2010-07-08       Impact factor: 10.121

Review 3.  Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

Authors:  Chiara Poluzzi; Renato V Iozzo; Liliana Schaefer
Journal:  Adv Drug Deliv Rev       Date:  2015-10-27       Impact factor: 15.470

4.  Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization.

Authors:  A Pozzi; P E Moberg; L A Miles; S Wagner; P Soloway; H A Gardner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

5.  Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding.

Authors:  Z Chang; A Choon; A Friedl
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

6.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin.

Authors:  Yuki Hamano; Michael Zeisberg; Hikaru Sugimoto; Julie C Lively; Yohei Maeshima; Changqing Yang; Richard O Hynes; Zena Werb; Akulapalli Sudhakar; Raghu Kalluri
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

Review 7.  The role of angiogenesis in human non-Hodgkin lymphomas.

Authors:  Domenico Ribatti; Beatrice Nico; Girolamo Ranieri; Giorgina Specchia; Angelo Vacca
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

8.  Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin.

Authors:  T Sasaki; N Fukai; K Mann; W Göhring; B R Olsen; R Timpl
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

Review 9.  Cellular actions and signaling by endostatin.

Authors:  Ramani Ramchandran; S Ananth Karumanchi; Jun-ichi Hanai; Seth L Alper; Vikas P Sukhatme
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2002       Impact factor: 1.807

10.  Crystal structure of human collagen XVIII trimerization domain: A novel collagen trimerization Fold.

Authors:  Sergei P Boudko; Takako Sasaki; Jürgen Engel; Thomas F Lerch; Jay Nix; Michael S Chapman; Hans Peter Bächinger
Journal:  J Mol Biol       Date:  2009-07-23       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.